All The Claims

1. A protector structure for an electric power feeding apparatus comprising a curved wall portion provided at one wall of an upwardly extending guiding cylinder of a protector, the curved wall portion continuing to a top opening of the guiding cylinder such that a wiring harness is bendably pulled out along the curved wall portion, and the curved wall portion having a first side opening for exiting of a foreign matter, the first side opening being proximate to the opening.
2. A protector structure for an electric power feeding apparatus comprising:
a curved wall portion provided at one side wall of an upwardly extending guiding cylinder of a protector having a first side opening, the curved wall portion continuing to a top opening of the guiding cylinder such that a wiring harness is bendably pulled out along the curved wall portion;
an other side wall of the guiding cylinder; and
a second side opening for exiting of a foreign matter provided on the other side wall of the guiding cylinder, the second side opening being proximate to the top opening and the other side wall being opposite the curved wall portion of the guiding cylinder.
3. The protector structure for the electric power feeding apparatus according to claim 2, further comprising a projection provided inside of the guiding cylinder and on the other side wall thereof, the projection projecting from a lower side of the side opening and having an upwardly sloping surface continuing to the side opening.
4. The protector structure for the electric power feeding apparatus according to claim 2, further comprising a projection provided inside of the guiding cylinder and on the other side wall thereof, the projection projecting from an upper side of the side opening and traversing inside of the guiding cylinder.
5. The protector structure for the electric power feeding apparatus according to claim 4, wherein the protector includes two separate protector members, the one separate protector member having the projection that extends towards the other separate protector member such that a joining area between the separate protector members is covered by the projection.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of the formula I:
or a pharmaceutically acceptable salt or solvate of said compound, wherein:
L1 is a covalent bond, \u2014CH2\u2014, \u2014C(O)\u2014, \u2014C(O)O\u2014, \u2014S(O2)\u2014, \u2014S(O)\u2014, \u2014S\u2014, \u2014O\u2014, \u2014NH\u2014, or
L2 is \u2014CH2\u2014, \u2014C(H)(alkyl)-, \u2014C(alkyl)2\u2014, \u2014C(O)\u2014, \u2014SO\u2014, \u2014S(O2,)\u2014, \u2014C(\u2550NR7)\u2014, \u2014C(\u2550N\u2014CN)\u2014 or \u2014C(\u2550N\u2014OR7);
L3 is a covalent bond, \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is selected from the group consisting of H, halogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, \u2014NHR7, \u2014N(R7)2, \u2014C(O)R7, \u2014C(O)OR7, \u2014S(O2) R7, \u2014Si(alkyl)n(aryl)3-n, aryl and heteroaryl, wherein each of said aryl or heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, alkoxy, \u2014N(R7)2, \u2014C(O)OR7, \u2014C(O)N(R7)2, \u2014NC(O)R7, \u2014NC(O)OR7, \u2014NC(O)N(R7)2, \u2014NO2, \u2014CN, \u2014S(O2)R7, \u2014S(O2)N(R7)2, \u2014NC(\u2550N\u2014CN)NHR7, and OH, with the proviso that:
e) when R1 is halogen, L1 is a covalent bond;
f) when R1 is \u2014NHR7 or \u2014N(R7)2, L1 is a covalent bond, \u2014CH2\u2014, \u2014C(O)\u2014, \u2014S(O2)\u2014 or \u2014SO\u2014;
g) when R1 is \u2014C(O)R7 or \u2014C(O)OR7, L1 is a covalent bond, \u2014CH2\u2014, \u2014NH\u2014 or \u2014N(alkyl)-; and
h) when R1 is \u2014S(O2)R7 or \u2014C(O)OR7, L1 is a covalent bond, \u2014CH2\u2014, \u2014NH\u2014 or \u2014N(alkyl)-;

R2 is H, \u2014OH, halogen, \u2014N(R7)2\u2014, \u2014CF3, alkoxy, alkyl, haloalkyl, cycloalkyl or cycloalkylalkyl;
R3 and R4 are the same or different, and are independently H or alkyl, or R3 and R4 taken together form a carbonyl group, i.e. C(\u2550O);
R5 is H or alkyl;
R6 is selected from the group consisting of H, alkyl, haloalkyl, cycloalkyl, NHR7, N(R7)2, aryl and heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which moieties can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, alkoxy and OH;
R7 is selected from H, alkyl, haloalkyl, cycloalkyl, heterocyclylalkyl, aryl and heteroaryl, wherein each of said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which moieties can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, alkoxy andor OH;
A is selected from phenyl, naphthyl, pyridyl, thienyl, thiazolyl, quinolyl, isoquinolyl, pyrazinyl, pyridazinyl, furanyl, pyrrolyl, pyrimidyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, benzofuranyl, and benzothienyl;
X is independently selected from the group consisting of H, halogen, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, alkoxycarbonyl, haloalkoxy, \u2014N(R7)2, \u2014N(R7)(C(O)R7), \u2014N(R7)(C(O)OR7), \u2014NO2 and \u2014CN, and when A is selected from the group consisting of pyridyl, thienyl, thiazolyl, quinolyl, isoquinolyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrimidyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, and benzothienyl, X can be oxide; and
n is 0-3,
with the proviso that (i) the two R7 moieties in \u2014N(R7)2 can be the same or different and are independently selected, and (ii) the moiety \u2014N(R5)-L3-R6 can optionally form a ring system.
2. A compound according to claim 1 wherein
L1 is \u2014CH2\u2014, \u2014C(O)\u2014, \u2014S(O)\u2014, \u2014C(O)O\u2014, or \u2014S(O2)\u2014;
L2 is \u2014CH2\u2014, \u2014CH(alkyl), \u2014C(alkyl)2\u2014, \u2014C(O)\u2014, \u2014SO\u2014 or \u2014S(O2)\u2014;
L3 is \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, \u2014N(R7)2, \u2014CN, (C1-C6)alkoxy and OH;
R2 is H, OH, halogen, CF3, alkoxy, \u2014N(R7)2, (C1-C6)alkyl, (C1-C6)haloalkyl, \u2014CH2\u2014(C3-C5)cycloalkyl, or (C3-C5)cycloalkyl;
R3 and R4 are the same or different, and are independently selected from H or (C1-C6)alkyl;
R5 is H or (C1-C6)alkyl;
R6 is H, (C1-C6)alkyl, or haloalkyl;
A is phenyl, naphthyl, furanyl or pyridyl;
X is selected from the group consisting of H, halogen, alkyl, haloalkyl, (C3-C5)cycloalkyl, hydroxy, alkoxy, and haloalkoxy and
n is 0-2.
3. A compound according to claim 1 wherein
L1 is \u2014CH2\u2014, \u2014C(O)O\u2014 or \u2014S(O2)\u2014;
L2 is \u2014CH2\u2014 or \u2014S(O2)\u2014;
L 3 is \u2014C(O)\u2014 or S(O2)\u2014;
R1 is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, (C1-C6)alkoxy and OH;
R2 is H, OH, halogen, CF3, alkoxy, (C1-C6)alkyl, (C1-C6)haloalkyl, \u2014CH2\u2014(C3-C5)cycloalkyl or (C3-C5)cycloalkyl;
R3 and R4 are H;
R5 is H or C1-C6 alkyl;
R6 is H, C1-C6 alkyl, or haloalkyl;
A is phenyl or pyridyl;
X is selected from the group consisting of H, halogen, alkyl, haloalkyl, (C3-C5)cycloalkyl, hydroxy, alkoxy, and haloalkoxy and
n is 0-2.
4. The compound according to claim 1 having the formula 2:
wherein:
L3 is \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, (C1-C6)alkoxy and OH;
R2 is H, OH, F, (C1-C6)alkyl, (C1-C6)haloalkyl, alkoxy or (C3-C5)cycloalkyl;
R6 is H, C1-C6 alkyl, or haloalkyl;
X is selected from the group consisting of H, halogen, alkyl, haloalkyl, (C3-C5)cycloalkyl alkoxy, hydroxy and haloalkoxy and
n is 0-2.
5. The compound according to claim 1 having the formula 3:
wherein:
L3 is \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one to five moieties which can be the same or different and are independently selected from the group consisting of halogen, alkyl, cycloalkyl, haloalkyl, haloalkoxy, (C1-C6)alkoxy and OH;
R2 is H, OH, F, (C1-C6)alkyl, (C1-C6)haloalkyl, alkoxy or (C3-C5)cycloalkyl;
R6 is H, C1-C6 alkyl, or haloalkyl;
X is selected from the group consisting of H, halogen, alkyl, haloalkyl, (C3-C5)cycloalkyl, alkoxy, hydroxy and haloalkoxy and
n is 0-2.
6. The compound according to claim 1 wherein:
L1 is \u2014C(O)O\u2014 or \u2014S(O2)\u2014;
L2 is \u2014S(O2)\u2014;
L3 is \u2014C(O)\u2014 or \u2014S(O2)\u2014;
R1 is selected from the group consisting of t-butyl, i-propyl, neopentyl, 2-trifluoromethyl-2-propyl, 1,1-bis(trifluoromethyl)-1-ethyl, 2-fluorophenyl, 2,6-difluorophenyl, 2-pyridyl, and 2-pyrimidyl;
R2 is H, F, (C1-C6)alkyl, OH, or alkoxy;
R3\u2550R4\u2550H;
R5 is H;
R6 is CH3 or CF3;
A is phenyl, indolyl or pyridyl;
X is selected from the group consisting of H, F, Cl, Br, CF3, \u2014OCH3, \u2014OCF3 and \u2014OCHF2; and
n is 0-2.
7. The compound according to claim 1 of the formula:
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A, L1, L2, L3 and X are as set forth in the following table:
Cmp
R1
R2
R3
R4
R6
A =
L1
L2
L3
X
A
H
H
H
CF3
CO2
SO2
SO2
Cl

B
H
H
H
CH3
CO2
SO2
SO2
OCF3

C
H
H
H
CF3
CO2
SO2
SO2
Cl

D
H
H
H
CF3
CO2
SO2
SO2
H

E
H
H
H
CF3
CO2
SO2
SO2
Cl

F
H
H
H
CH3
CO2
SO2
SO2
Cl

G
H
H
H
CF3
CO2
SO2
SO2
Cl

H
i-propyl
H
H
H
CF3
CO2
SO2
SO2
Cl

I
H
H
H
CH3
CO2
SO2
SO2
H

J
H
H
H
CH3
SO2
SO2
SO2
OCH3

K
H
H
H
CH3
SO2
SO2
SO2
OCH3

L
H
H
H
CH3
SO2
SO2
SO2
OCF2H

M
H
H
H
CH3
SO2
SO2
SO2
OCF3

N
H
H
H
C2H5
SO2
SO2
SO2
OCF2H

O
H
H
H
CH3
SO2
SO2
SO2
Cl

P
H
H
H
C2H5
SO2
SO2
SO2
OCF3

Q
H
H
H
CF3
SO2
SO2
SO2
CF3

R
H
H
H
CF3
SO2
SO2
SO2
Cl

S
H
H
H
CF3
SO2
SO2
C\u2550O
OCH3

T
H
H
H
CH3
SO2
SO2
SO2
H

U
H
H
H
CF3
SO2
SO2
C\u2550O
OCH3

V
Br
H
H
H
CH3
CB
SO2
SO2
H

W
H
H
H
CH3
CB
SO2
SO2
H

X
C3H7
H
H
H
CH3
SO2
SO2
SO2
OCH3

Y
H
H
H
CF3
SO
SO2
C\u2550O
Cl

Z
H
H
H
CF3
SO2
CH2
C\u2550O
Cl

AA
H
H
H
CF3
S
CH2
C\u2550O
Cl

AB
H
H
H
CH3
CH2
SO2
SO2
Cl

AC
H
H
H
CH3
CH2
SO2
SO2
Cl

AD
H
H
H
CH3
C\u2550O
SO2
SO2
Cl

AE
H
H
H
H
CF3
CB
SO2
SO2
H

AF
H
H
H
H
CH3
CB
SO2
SO2
H

AG
H
H
H
CH3
SO2
SO2
SO2
H

AH
Si(CH3)3
H
H
H
CH3
CB
SO2
SO2
Cl

Al
Br
H
H
H
CH3
CB
SO2
SO2
H

AJ
H
H
H
CH3
NH
SO2
SO2
H

AK
OCH3
H
H
CH3
CO2
SO2
SO2
Cl

AL
CH3
H
H
CF3
SO2
SO2
SO2
Cl

AM
CH3
H
H
CH3
SO2
SO2
SO2
Cl

AN
CH3
H
H
CF3
CO2
SO2
SO2
Cl

AP
H
H
H
CF3
CO2
SO2
SO2
OCH3

AQ
F
H
H
CF3
SO2
SO2
SO2
Cl

AR
F
H
H
CF3
CO2
SO2
SO2
Cl

AS
F
H
H
CF3
SO2
SO2
SO2
Cl

AU
F
H
H
CF3
SO2
SO2
SO2
Cl

AV
OCH3
H
H
CF3
SO2
SO2
SO2
Cl

AW
OCH3
H
H
CF3
SO2
SO2
SO2
Cl

AX
OCH3
H
H
CF3
CO2
SO2
SO2
Cl

AY
H
H
H
CH3
SO2
SO2
SO2
OCF3

AZ
H
H
H
CF3
SO2
SO2
SO2
OCF3

BA
H
H
H
CF3
SO2
SO2
SO2
Cl

BD
H
H
H
CF3
CO2
SO2
SO2
OCF3

BE
H
H
H
CF3
CO2
SO2
SO2
Cl

BF
H
CH3
CH3
CF3
SO2
SO2
SO2
Cl

BG
H
CH3
CH3
CF3
SO2
SO2
C\u2550O
CF3

BH
H
CH3
CH3
CF3
SO2
SO2
C\u2550O
Cl

BI
H
CH3
CH3
CF3
SO2
SO2
SO2
CF3

BJ
H
CH3
CH3
H
SO2
SO2
CB
CF3

BK
H
CH3
CH3
CF3
CO2
SO2
SO2
Cl

BL
F
H
H
CF3
SO2
SO2
SO2
CF3

BM
OCH3
H
H
CF3
S
SO2
SO2
Cl

BN
F
H
H
CF3
CO2
SO2
SO2
CF3

BO
F
H
H
CF3
SO2
SO2
SO2
Cl

BP
OH
H
H
CF3
CO2
SO2
SO2
Cl

BQ
H
H
CH3
CO2
SO2
SO2
Cl

BR
F
H
H
CF3
SO2
SO2
SO2
Cl

BS
H
H
CH3
CO2
SO2
SO2
Cl

BT
CH3
H
H
CF3
SO2
SO2
C\u2550O
Cl

BU
H
H
CF3
CO2
SO2
SO2
Cl

BV
OH
H
H
CH3
CO2
SO2
SO2
Cl

BW
F
H
H
CF3
SO2
SO2
C\u2550O
Cl

BX
C3H7
H
H
CF3
CO2
SO2
SO2
Cl

BY
F
H
H
CF3
SO2
SO2
SO2
Cl

BZ
H
H
CF3
CO2
SO2
SO2
Cl

CA
H
H
H
CF3
SO2
SO2
C\u2550O
Cl

CB
H
H
H
CF3
SO2
SO2
SO2
H

CC
H
H
H
CF3
SO2
SO2
SO2
Cl

CD
H
H
H
CF3
SO2
SO2
C\u2550O
Cl

CE
H
H
H
CF3
SO2
SO2
C\u2550O
OCF2H

CF
H
H
H
CH3
SO2
SO2
SO2
H

CG
H
H
H
CF3
SO2
SO2
C\u2550O
H

CH
H
H
H
CF3
SO2
SO2
C\u2550O
OCH3

CI
H
H
H
C2H5
SO2
SO2
SO2
OCF3

CJ
H
H
H
CH3
SO2
SO2
SO2
OCF3

CK
H
H
H
CF3
SO2
SO2
SO2
OCF3

CL
H
H
H
CF3
SO2
SO2
C\u2550O
OCF3

CM
H
H
H
CF3
SO2
SO2
C\u2550O
CF3

CN
H
H
H
CF3
SO2
SO2
C\u2550O
OCF3

CO
H
H
H
CH3
SO2
SO2
SO2
Cl

CP
C4H9
H
H
H
CH3
SO2
SO2
SO2
Cl

CQ
H
H
H
C2H5
CO2
SO2
SO2
Cl

CR
CH3
H
H
H
CF3
CO2
SO2
C\u2550O
H

CS
H
H
H
CF3
CO2
SO2
SO2
CF3

CT
H
H
H
CF3
CB
SO2
C\u2550O
H

CU
H
H
H
CH3
CB
SO2
SO2
H

CV
Cl
H
H
H
CH3
CB
SO2
SO2
Br

CW
H
H
H
CH3
CB
SO2
SO2
H

CX
F
H
H
CF3
CO2
SO2
C\u2550O
Cl

CY
H
H
H
H
CH3
CB
SO2
SO2
H

DA
F
H
H
CF3
SO
SO2
SO2
Cl

DB
F
H
H
CF3
SO
SO2
SO2
Cl

DC
H
H
H
CF3
SO2
CH2
C\u2550O
OCF3

DD
CH3
H
O*
O*
H
CO2
SO2
CB
H

DE
H
H
H
CH3
CB
SO2
SO2
H

DF
H
H
H
CH3
CB
SO2
SO2
H

DG
H
H
H
N(CH3)2
CO2
SO2
SO2
Cl

DH
Br
H
H
H
CH3
CB
SO2
SO2
H

DI
CH3
H
H
H
CH3
CB
SO2
SO2
t-butyl

DK
OCH3
H
H
CF3
SO2
SO2
SO2
Cl

DL
OC2H5
H
H
H
S
SO2
CB
Cl

DM
OCH3
H
H
CH3
SO2
SO2
SO2
Cl

DN
F
H
H
CF3
SO
SO2
SO2
Cl

DO
OC2H5
H
H
CF3
SO2
SO2
SO2
Cl

DP
OCH3
H
H
CH3
SO2
SO2
SO2
Cl

DQ
F
H
H
CF3
SO2
SO2
SO2
Cl

DR
F
H
H
CF3
SO2
SO2
SO2
Cl

DS
F
H
H
CF3
SO2
SO2
SO2
Cl

DT
CH3
H
H
H
CH3
SO2
SO2
SO2
Cl
CB = covalent bond
*R3 and R4 taken together form a carbonyl group (C\u2550O).
8. The compound according to claim 1 having the formula:
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R6, A, L1, and X are as set forth in the following table:
Cmp.
R1
R2
R6
A
L1
X
A
H
CF3
CO2
Cl

C
H
CF3
CO2
Cl

D
H
CF3
CO2
H

E
H
CF3
CO2
Cl

F
H
CH3
CO2
Cl

G
H
CF3
CO2
Cl

H
i-propyl
H
CF3
CO2
Cl

J
H
CH3
SO2
OCH3

L
H
CH3
SO2
OCF2H

M
H
CH3
SO2
OCF3

N
H
C2H5
SO2
OCF2H

Q
H
CF3
SO2
CF3

AK
OCH3
CH3
CO2
Cl

AL
CH3
CF3
SO2
Cl

AM
CH3
CH3
SO2
Cl

AN
CH3
CF3
CO2
Cl

AP
H
CF3
CO2
OCH3

AQ
F
CF3
SO2
Cl

AR
F
CF3
CO2
Cl

AS
F
CF3
SO2
Cl

AU
F
CF3
SO2
Cl

AV
OCH3
CF3
SO2
Cl

AW
OCH3
CF3
SO
Cl

AX
OCH3
CF3
CO2
Cl

AZ
H
CF3
SO2
OCF3

BD
H
CF3
CO2
OCF3

BE
H
CF3
CO2
Cl

DK
OCH3
CF3
SO2
Cl

DM
OCH3
CH3
SO2
Cl

DO
OC2H5
CF3
SO2
Cl

DP
OCH3
CH3
SO2
Cl
CB = covalent bond
* R3 and R4 taken together form a carbonyl group (C\u2550O).
9. The compound according to claim 1 having the formula:
10. The compound according to claim 1 having the formula:
11. The compound according to claim 1 having the formula:
12. The compound according to claim 1 having the formula:
13. The compound according to claim 1 having the formula:
14. The compound according to claim 1 having the formula:
15. The compound according to claim 1 having the formula:
16. The compound according to claim 1 having the formula:
17. The compound according to claim 1 having the formula:
18. The compound according to claim 1 having the formula:
19. The compound according to claim 1 having the formula:
20. The compound according to claim 1 having the formula:
21. The compound according to claim 1 having the formula:
22. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition comprising an effective amount of a compound according to claim 9 and a pharmaceutically acceptable carrier.
24. A pharmaceutical composition comprising an effective amount of a compound according to claim 10 and a pharmaceutically acceptable carrier.
25. A method of treating cancer, inflammatory diseases, immunomodulatory diseases, or respiratory diseases comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 1.
26. A method of treating cutaneous T cell lymphoma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, sepsis, shock, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing aveolitis, psoriasis, transplant rejection, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn’s disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD) or bronchitis comprising administering to a mammal in need of such treatment an effective amount of a compound according to claim 1.
27. The method of claim 25 wherein the condition or disease treated is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, seasonal allergic rhinitis, psoriasis, transplant rejection and chronic obstructive pulmonary disease.
28. A process for making a pharmaceutical composition comprising combining a compound of claim 1 and a pharmaceutically acceptable carrier.
29. A method of treating rheumatoid arthritis comprising administering to a mammal in need thereof an effective amount of a compound of claim 1 in combination with at least one compound selected from the group consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid and an anti-TNF-\u03b1 compound.
30. A method of treating rheumatoid arthritis comprising administering to a mammal in need thereof an effective amount of a compound of claim 10 in combination with at least one compound selected from the group consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid and an anti-TNF-\u03b1 compound.
31. The method of claim 29 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunomide, sulfasalazine, or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
32. The method of claim 30 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunomide, sulfasalazine, or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
33. A composition for treating rheumatoid arthritis which comprises an effective amount of a compound of claim 1 and a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid and an anti-TNF-\u03b1 compound.
34. A composition for treating rheumatoid arthritis which comprises an effective amount of a compound of claim 10 and a compound selected from the class consisting of a COX-2 inhibitor, a COX-1 inhibitor, an immunosuppressive, a steroid and an anti-TNF-\u03b1 compound.
35. The composition of claim 33 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunomide, sulfasalazine, or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
36. The composition of claim 34 wherein the COX-2 inhibitor is Celebrex or Vioxx, the COX-1 inhibitor is Feldene, the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
37. A method of treating multiple sclerosis comprising administering to a mammal in need thereof an effective amount of a compound of claim 1 in combination with an effective amount of a compound selected from the group consisting of Avonex, Betaseron and Copaxone.
38. A method of treating multiple sclerosis comprising administering to a mammal in need thereof an effective amount of a compound of claim 10 in combination with an effective amount of a compound selected from the group consisting of Avonex, Betaseron and Copaxone.
39. A composition for treating multiple sclerosis which comprises an effective amount of a compound of claim 1 and a compound selected from Avonex, Betaseron and Copaxone.
40. A composition for treating multiple sclerosis which comprises an effective amount of a compound of claim 10 and a compound selected from the group consisting of Avonex, Betaseron and Copaxone.
41. A method of treating psoriasis comprising administering to a mammal in need thereof an effective amount of a compound as defined in claim 1 in combination with a compound selected from the group consisting of an immunosuppressive, a steroid and anti-TNF-\u03b1 compound.
42. A method of treating psoriasis comprising administering to a mammal in need thereof an effective amount of a compound as defined in claim 10 in combination with a compound selected from the group consisting of an immunosuppressive, a steroid and anti-TNF-\u03b1 compound.
43. The method of claim 41 wherein the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
44. The method of claim 42 wherein the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
45. A composition for treating psoriasis which comprises an effective amount of a compound of claim 1 and a compound selected from the group consisting of an immunosuppressive, a steroid and anti-TNF-\u03b1 compound.
46. A composition for treating psoriasis which comprises an effective amount of a compound of claim 10 and a compound selected from the group consisting of an immunosuppressive, a steroid and anti-TNF-\u03b1 compound.
47. The composition of claim 45 wherein the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
48. The composition of claim 46 wherein the immunosuppressive is methotrexate, leflunomide, sulfasalazine or cyclosporin, the steroid is \u03b2-methasone and the anti-TNF-\u03b1 compound is Enbrel or Remicade.
49. A method of treating seasonal allergic rhinitis andor asthma comprising an effective amount of a compound of claim 1 in combination with an H1 antagonist.
50. A composition for treating seasonal allergic rhinitis andor asthma which comprises an effective amount of an H1 antagonist and an effective amount of a compound of claim 1.
51. The composition of claim 50 wherein the H1 antagonist is selected from the group consisting of Claritin, Clarinex, Zyrtec and Allegra.

1. An image processing device that converts a color value on a first color space into a different color value corresponding to a second color on a second color space, the device comprising:
a first color conversion unit that converts the color value in the first color space into the different color value without adjusting a gray axis; and
a second color conversion unit that adjusts the gray axis in the first color space after the color value has been converted into the different color value.
2. The image processing device according to claim 1,
the first color conversion unit converting the color value in accordance with a first color conversion table that correlates the color value on a part other than the gray axis with a correlating color value and adapts the color value on the part other than the gray axis to the second color of the second color space.
3. A color conversion table creating device that creates a color conversion table for performing a color conversion of a color value on a first color space into a color value on a second color space, the device comprising:
a first color space setting unit that sets a color area of the first color space; and
a first color conversion table creating unit that (1) converts the color value in the set color area of the first color space without converting a gray axis part of the color value and (2) creates a first color conversion table that correlates the color value on a part other than the gray axis part with a correlating color value that adapts the color value on the part other than the gray axis part to the color value on the second color space.
4. The color conversion table creating device according to claim 3, further comprising a second color conversion table acquiring unit that acquires a second color conversion table to adjust a gray axis part of the color value of the second color space with respect to the color value on the first color space.
5. The color conversion table creating device according to claim 4,
the first color conversion table creating unit converting the color value on the first color space into a device-independent color value on a device-independent color space, and in the device-independent color space, corrects the gray axis part of the color value on the first color space to the color value on the gray axis part adjusted by the second color conversion table in the second color space so as to not convert the corrected gray axis part of the color value on the first color space.
6. The color conversion table creating device according to claim 5, the first color conversion table creating unit correlating, for the color value on the part other than the gray axis part in the first color space, a color value closer to the gray axis part of the first color space with a color value closer to the gray axis part in the second color space, in the device-independent color space.
7. The color conversion table creating device according to claim 6, the first color conversion table creating unit carrying out the color conversion to the second color space from the device-independent color space in consideration of the output characteristic of a display device after the application of the second color conversion table.
8. The color conversion table creating device according to claim 4, the first color conversion table creating unit correlating the color value on the part other than the gray axis part on the first color space so that the color value of low saturation comes close to the color value on the first color space and so that the color value of high saturation comes close to the color value on the second color space.
9. The color conversion table creating device according to claim 8, the first color conversion table creating unit correlating an outermost color value of the color area in the first color space with an outermost color value of the color area in the second color space.
10. The color conversion table creating device according to claim 8, the first color conversion table creating unit converting the color value on the first color space into a color value on an HSI color space to correlate the color value in the HSI color space.
11. The color conversion table creating device according to claim 8, the first color conversion table creating unit carrying out the color conversion to the second color space from the HSI color space in consideration of an output characteristic of the display device after the application of the second color conversion table.
12. The color conversion table creating device according to claim 8, the first color conversion table creating unit adjusting the range of the color value of high saturation.
13. The color conversion table creating device according to claim 8, the first color conversion table creating unit adjusting a change amount of a hue by the color conversion of the first color conversion table.
14. A display device comprising the image processing device of claim 1.
15. An image processing method that converts a color value on a first color space into a different color value corresponding to a second color on a second color space, the method comprising:
a first color conversion process that converts the color value in the first color space into the different color value without adjusting the gray axis; and
a second color conversion process that adjusts the gray axis in the first color space after the color value has been converted into the different color value.
16. A color conversion table creating method that creates a color conversion table for performing a color conversion of a color value on a first color space into a color value on a second color space, the method comprising:
a first color space setting process that sets a color area of the first color space; and
a first color conversion table creating process that (1) converts the color value in the set color area of the first color space without converting a gray axis part of the color value and (2) creates a first color conversion table that correlates the color value or the part other than the gray axis part with a correlating color value that adapts the color value on the part other than the gray axis part to the color value on the second color space.
17. A method of manufacturing a display device that carries out color conversion in accordance with a color conversion table, the method comprising:
a first color space setting process that sets a color area of the first color space;
a first color conversion table creating process that (1) converts the color value in the set color area of the first color space without converting a gray axis part of the color value and (2) creates a first color conversion table that correlates the color value on the part other than the gray axis part with a correlating color value that adapts the color value on the part other than the gray axis part to the color value on the second color space; and
a table storing process that stores the created first color conversion table in the display device.
18. A display device comprising:
a color mode setting unit that sets a color mode;
a color output characteristic data generating unit that outputs a screen of a prescribed color;
a detecting unit that detects the color tones of the screen;
a second color conversion table creating unit that determines a target gray characteristic corresponding to the set color mode and creates a second color conversion table that calculates output values and correlates a gray-axis part of the detected color tones with the output values;
a second color conversion executing unit that corrects the detected color tones without adjusting the gray axis in accordance with the output values of the second color conversion table, and outputs the corrected color tones; and
a first color conversion table creating unit that conducts a gray axis correction of the corrected color tones.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An ink for ink jet recording, comprising an aqueous medium and a magenta dye dissolved or dispersed in the aqueous medium, the magenta dye being selected from azo dyes,
wherein the magenta dye has an absorption maximum in a spectral range of from 500 to 580 nm in the aqueous medium and an oxidation potential of more positive than 1.0 V (vs SCE), and
the azo dye is a dye represented by the following formula (1): Formula (1)
wherein A represents a 5-membered heterocyclic ring group; B1 and B2 each represents \u2550CR1\u2014 or \u2014CR2\u2550 or one of B1 and B2 represents a nitrogen atom while other represents \u2550CR1\u2014 or \u2014CR2\u2550; R5 and R6 each independently represents a hydrogen atom or a substituent which is an aliphatic group, an aromatic group, a heterocyclic ring, an acyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, a carbamoyl group, an alkylsulfonyl group, an arylsulfonyl group or a sulfamoyl group, a hydrogen atom of the substituent may be substituted: G, R1 and R2 each independently represents a hydrogen atom or a substituent which is a halogen atom, an aliphatic group, an aromatic group, a heterocyclic ring group, a cyano group, a carboxyl group, a carbamoyl group, an alkoxycarbonyl group, an aryloxycarbonyl group, a heterocyclic oxycarbonyl group, an acyl group, a hydroxy group, an alkoxy group, an aryloxy group, a heterocyclic oxy group, a silyloxy group, an acyloxy group, a carbamoyloxy group, an alkoxycarbonyloxy group, an aryloxycarbonyloxy group, an amino group, an acylamino group, an ureido group, a sulfamoylamino group, an alkoxycarbonylamino group, an aryloxycarbonylamino group, an alkylsulfonylamino group, an arylsulfonylamino group, a heterocyclic sulfonylamino group, a nitro group, an alkylthio group, an arylthio group, a heterocyclic thio group, an alkylsulfonyl group, an arylsulfonyl group, a heterocyclic sulfonyl group, an alkylsulfinyl group, an arylsulfinyl group, a heterocyclic sulfinyl group, a sulfamoyl group or a sulfo group, wherein a hydrogen atom of the substituent may be substituted; and R1 and R5 or R5 and R6 may be connected to each other to form a 5- or 6-membered ring.
2. The ink for ink jet recording according to claim 1, wherein the azo dye has one of an aromatic cyclic amino group and a heterocyclic amino group-containing structure as an auxochrome.
3. The ink for ink jet recording according to claim 1, wherein the azo dye has a stereostructure.
4. The ink for ink jet recording according to claim 1,
wherein the ink has an ozone fading rate constant of a recorded image, the ozone fading rate constant is 5.0\xd710\u22122hr\u22121 or less.
5. The ink for ink jet recording according to claim 1, which has a viscosity of from 1 to 20 mPa\xb7sec at 25\xb0 C.
6. The ink for ink jet recording according to claim 1, which has a static surface tension of from 25 to 50 mNm at 25\xb0 C.
7. The ink for ink jet recording according to claim 1, which has an electrical conductance of from 0.01 to 10 Sm.
8. The ink for ink jet recording according to claim 1,
wherein a change of a viscosity and a surface tension of the ink from at 25\xb0 C. to at 10\xb0 C. are 250% or less and 130% or less, respectively.
9. The ink for ink jet recording according to claim 1,
wherein the ink has no visibly detectable bleeding on an image-receiving material at a visible distance, the image-receiving material comprises an image-receiving layer on a support, and the image-receiving layer contains a white inorganic pigment particle.
10. The ink for ink jet recording according to claim 1,
which has no visibly detectable bleeding on an image-receiving material at a visible distance, the image-receiving material comprising a gelatin-containing hardened layer as an image-recording layer.
11. A method for producing the ink for ink jet recording according to claim 1,
which comprises a step of dissolving or dispersing the azo dye in the aqueous medium with an ultrasonic agitation.
12. A method for producing the ink for ink jet recording according to claim 1,
which comprises steps of: filtering the aqueous medium having the azo dye dissolved or dispersed in the aqueous medium through a filter having an effective pore diameter of 1 \u03bcm or less; and defoaming the filtered aqueous medium.
13. An ink jet recording method using the ink for ink jet recording according to claim 1.
14. The ink jet recording method according to claim 13,
wherein an ink droplet is ejected onto an image-receiving material in accordance with a recording signal so that an image is recorded on the image-receiving material by using the ink for ink jet recording, the image-receiving material comprising an image-receiving layer on a support, the image-receiving layer containing a white inorganic pigment particle.
15. The ink jet recording method according to claim 14,
wherein the image-receiving layer contains the white inorganic pigment particle and at least one aqueous binder selected from the group consisting of a polyvinyl alcohol, a silanol-modified polyvinyl alcohol, a starch, a cationated starch, a gelatin, a carboxyalkyl cellulose, a casein and a polyvinyl pyrrolidone.
16. The ink jet recording method according to claim 15, wherein the image-receiving layer further contains a mordant selected from the group consisting of a polyaluminum chloride, a chromium compound and an azo dye-mordanting group-containing polymer.